TriSalus Life Sciences, Inc. TLSI

4.34 (0.27) (5.86%) as of 25 Sep
Market cap
$303.6M
P/E
0.0×
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '17
P/E ratio
0.00 0.00 0.00 0.00 — — —
P/S ratio
5.86 4.31 4.19 0.00 — — —
P/FCF ratio
0.00 0.00 0.00 0.00 — — —
P/Operating CF
(106.49) (22.24) (8.45) (0.37) — — —
P/B ratio
0.00 0.00 0.00 0.00 — — —
Price to Tangible BV
0.00 0.00 0.00 0.00 — — —
EV/Sales
6.14 4.78 3.64 0.00 — — —
EV/EBITDA
0.00 0.00 0.00 0.11 — — —
EV/Operating CF
(15.40) (3.45) (1.33) 0.12 — — —
EV/FCF
(14.16) (3.36) (1.30) 0.12 — — —
Quick Ratio
2.35 1.33 1.04 0.34 0.13 12.94 —
Current Ratio
2.80 2.02 1.42 0.53 0.33 19.46 —
Net Debt/EBITDA
(0.50) (0.39) 0.22 0.22 (0.11) 12.30 —
Debt/Assets
93.53% 92.13% 0.00% 6.10% 0.22% 0.00% 0.00%
Debt/Equity
(0.98) (0.85) 0.00 (0.01) (0.03) 0.00 —
Asset Turnover
1.52 1.21 0.79 0.09 0.00 0.00 —
Operating CF/Net income
0.26 1.23 0.80 0.65 (0.36) 0.95 —
Capex/Depreciation
(0.50) (0.25) (1.64) (1.97) — — —
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 —
ROE
233.25% 125.50% 62.54% 51.82% (24.96%) (0.60%) —
ROA
(235.03%) (136.85%) (273.01%) (36.71%) 1.90% (0.56%) —
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% —
Return on Tangible Assets
(309.01%) (274.43%) (769.44%) 387.36% (443.18%) (37.34%) —
Average Days of Receivables
53.01 63.09 70.08 45.84 — — —
Research and Development Expense of Revenue
33.14% 60.10% 161.17% 172.27% — — —
Selling, General and Administrative Expense of Revenue
111.11% 148.84% 219.04% 203.43% 0.00% 0.00% —
Intangible Assets out of Total Assets
0.00 0.00 0.05 0.04 0.00 0.00 0.00
Share Based Compensation of Revenue
20.22% 18.49% 7.57% 2.97% — — —
Graham Net Nets
(0.14) (0.23) (0.40) (58.13) — — —
Graham Number
6.07 5.53 46.62 1,395.74 — — —
Earnings Yield
(26.22%) (26.55%) (406.46%) (1,514.59%) — — —
Free Cash Flow Yield
(7.40%) (33.04%) (66.96%) (1,058.19%) — — —
Revenue per Share
1.19 1.16 1.97 39.99 0.00 0.00 —
Operating CF per Share
(0.48) (1.61) (5.38) (104.24) (0.28) (0.11) —
Capex per Share
(0.02) (0.01) (0.12) (2.54) 0.00 0.00 —
Free Cash Flow per Share
(0.50) (1.63) (5.50) (106.77) (0.28) (0.11) —
Cash per Share
0.54 0.34 1.25 30.37 0.03 0.21 —
Shareholders Equity per Share
(0.89) (1.02) (2.88) (568.81) (2.67) (3.40) —
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 —
Book value per Share
(0.89) (1.02) (2.88) (568.81) (2.67) (3.40) —
Free Cash Flow
(18.85) (41.19) (51.70) (33.10) (1.74) (0.68) —
Working Capital
20.75 10.44 6.18 (15.14) (1.08) 1.91 —
Capital Expenditures
(0.84) (0.34) (1.12) (0.79) — — —
Net Current Asset Value
(36.95) (29.20) (30.80) (181.11) (266.72) (271.49) —
EV/EBIT
0.00 0.00 0.00 0.11 — — —
Capex to Sales
0.02 0.01 0.06 0.06 — — —
Net Profit Margin
(154.35%) (112.92%) (343.59%) (403.42%) 0.00% 0.00% —
Price to Operating Income
0.00 0.00 0.00 0.00 — — —
Other line items
Depreciation/Fixed assets
0.93 0.81 0.33 0.18 — — —
Cash ROIC
(101.00%) (901.63%) 344.51% 20.86% 10.88% 3.36% —
Accounts Receivable Turnover
7.75 6.81 7.24 0.00 — — —
Accounts Payable Turnover
2.64 1.45 0.62 0.75 — — —
Inventory Turnover
1.96 1.24 1.30 0.00 — — —
Average Days of Payables
157.32 202.29 475.13 799.67 0.00 — —
Days of Inventory on Hand
161.25 360.11 356.59 237.78 — — —
Average Receivables
5.82 4.32 2.56 — — — —
Average Payables
2.64 2.83 4.17 3.00 — — —
Average Inventory
3.56 3.30 2.01 — — — —
Average Assets
29.65 24.28 23.30 136.26 251.27 126.01 —
Average Common Equity
(29.88) (26.48) (101.70) (96.52) (19.10) 119.14 —

Fold the line items

Columns are period end dates